Back

Targeting the source: in vivo CRISPR-based gene editing for ATTR-CM - Q&A from the audience

30 August 2026 (15:50 - 16:00)
Organised by: Logo
Congress Presentation Part of: Targeting the source: in vivo CRISPR-based gene editing for transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Open Access ESC Congress 2026 European Society of Cardiology

4 More presentations in this session

Presentation thumbnail
Welcome and introduction
Doctor A. Masri (Portland, US)
Presentation thumbnail
Complexities of patient care in ATTR amyloidosis
Assistant Professor J. Vaishnav (Baltimore, US)
Presentation thumbnail
The utility of CRISPR gene editing in cardiology
Professor R. Witteles (Stanford, US)
Presentation thumbnail
Exploring CRISPR-based gene editing in ATTR-CM
Doctor A. Masri (Portland, US)

Access the full session

Session thumbnail
Targeting the source: in vivo CRISPR-based gene editing for transthyretin amyloid cardiomyopathy (ATTR-CM)
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 15:50 CET
You may be interested in
thumbnail
Congress Presentation
Q&A
11 May 2023
thumbnail
Congress Session
The ESC Journal Family: focus on personalised care in different fields of cardiovascular medicine
31 August 2024
thumbnail
Congress Session
When to look for amyloidosis
18 May 2025
thumbnail
Congress Presentation
Towards clinical translation of gene editing into cardiovascular care
31 August 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources